Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity

• Main Authors: Chen, L. (Author), Gao, D. (Author), Gao, S. (Author), Guo, S. (Author), Han, M. (Author), He, J. (Author), Jin, G. (Author), Jing, W. (Author), Li, Y. (Author), Liu, Z. (Author), Shi, X. (Author), Tang, S. (Author), Wang, H. (Author), Wang, Y. (Author), Xu, X. (Author), Yuan, Q. (Author), Zhang, X. (Author), Zhang, Y. (Author), Zheng, K. (Author), Zhu, Y. (Author)
• Format: Article
• Language: English
• Published: Nature Research 2022
• Subjects: cancer; cell component; drug; integrated approach
• Online Access: View Fulltext in Publisher

 Chromatin accessibility plays an essential role in controlling cellular identity and the therapeutic response of human cancers. However, the chromatin accessibility landscape and gene regulatory network of pancreatic cancer are largely uncharacterized. Here, we integrate the chromatin accessibility profiles of 84 pancreatic cancer organoid lines with whole-genome sequencing data, transcriptomic sequencing data and the results of drug sensitivity analysis of 283 epigenetic-related chemicals and 5 chemotherapeutic drugs. We identify distinct transcription factors that distinguish molecular subtypes of pancreatic cancer, predict numerous chromatin accessibility peaks associated with gene regulatory networks, discover regulatory noncoding mutations with potential as cancer drivers, and reveal the chromatin accessibility signatures associated with drug sensitivity. These results not only provide the chromatin accessibility atlas of pancreatic cancer but also suggest a systematic approach to comprehensively understand the gene regulatory network of pancreatic cancer in order to advance diagnosis and potential personalized medicine applications. © 2022, The Author(s).